Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Trypanosoma brucei Cleavage and Polyadenylation Specificity Factor 3 (CPSF3) is a zinc-dependent metallo-beta-lactamase-like endonuclease essential for the survival of the parasite (Nare et al., 2017). It plays a critical role in the processing of precursor messenger RNA (pre-mRNA), specifically in the 3'-end cleavage and polyadenylation steps (Wall et al., 2018). In kinetoplastids like T. brucei, CPSF3 is also uniquely involved in the coupled process of trans-splicing, which is vital for the maturation of nearly all protein-coding transcripts (Hendriks et al., 2003). Because of its central role in gene expression and its structural differences from the human ortholog, it has emerged as a high-priority therapeutic target (Swinney et al., 2020). Small molecule inhibitors, particularly oxaboroles like AN15368 (DNDi-6148), have demonstrated potent activity by binding to the catalytic site and blocking mRNA maturation (Zhang et al., 2017). This inhibition leads to a rapid cessation of protein synthesis and subsequent parasite death, making it a promising target for treating Human African Trypanosomiasis (DNDi, 2021). The target's specificity is enhanced by the unique trans-splicing mechanism in trypanosomes, which is absent in human hosts (Palenchar & Bellofatto, 2006). Structural studies have confirmed that these inhibitors coordinate with the catalytic zinc ions in the active site, providing a clear mechanism for drug action (Wall et al., 2018).
Inhibition of the endonuclease activity of CPSF3, which blocks pre-mRNA processing and trans-splicing, leading to the accumulation of unprocessed transcripts and parasite death.
2 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Cleavage and polyadenylation specificity factor 73 kDa subunit (CPSF3) (CPSF3).